Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy.

NCT06706466 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 410

Last updated 2024-11-26

No results posted yet for this study

Summary

The SIIR during neoadjuvant therapy can serve as a specific biomarker for predicting the efficacy of immunotherapy in patients with advanced gastric cancer.

Conditions

Interventions

OTHER

observational study

Non-interventional

Sponsors & Collaborators

  • Chang-Ming Huang, Prof.

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-12-31
Completion
2024-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06706466 on ClinicalTrials.gov